Nuplazids website used to say they were going to test it as a monotherapy for schizophrenia. Instead they changed the same page to state they are assesing unmet need in schizophrenia. I guess this means it will not go to clinical trials or maybe it looks bad. It probably has to do with the qt interval prolongation. It would have been nice to have a med that doesnt effect dopamine.
1 Like
I just spend my days dreaming about iti-007 now anyway.
1 Like